Image courtesy of Bayer

Bayer invests USD 50 Million in eGenesis Series B financing round

Originally posted on Bayer.com

Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation

Bayer Photo
Research in the eGenesis laboratory, Cambridge, MA, USA

Leverkusen, Germany and Boston, Mass., November 7, 2019 – eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors, including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures, all participated.

eGenesis is committed to helping solve the global organ shortage by pioneering an alternative source of human-compatible organs. It is currently estimated that there are between 1.5 to 2 million people on the organ transplant waitlist globally. This financing will enable the acceleration of the eGenesis kidney xenotransplant program into the clinic, as well as support advancement of a range of other xenotransplant programs across islet cell, liver, heart, and lung. The focus of the company is to rapidly advance an entirely new set of options across the transplantation field.

“Leaps by Bayer” is built for the specific purpose of tackling fundamental breakthrough solutions in the fields of health and nutrition with the help of new technologies. Sustainable organ replacement is one of the ten areas of engagement and investment (called “leaps”) for Leaps by Bayer. “We believe eGenesis is poised to revolutionize the entire organ transplantation market. This could save lives in a way that was previously not thought possible just a few years ago,” noted Jürgen Eckhardt, Head of Leaps by Bayer. Eckhardt and Dr. Lucio Iannone will represent Leaps by Bayer by actively participating on the eGenesis Board of Directors.

“eGenesis has a bold vision to solve the organ shortage crisis through xenotransplantation,” said Paul Sekhri, president and chief executive officer of eGenesis. “As we look ahead, we are proud to partner with Leaps by Bayer who has demonstrated a commitment for ushering in paradigm-shifting advances in the life sciences that will bring forward tomorrow’s medicines.”

Kemal Malik, Member of the Board of Management, Bayer AG, and responsible for Innovation, added, “Within Bayer’s innovation strategy, Leaps is driving breakthrough invention at Bayer and the eGenesis approach represents a truly transformational option, addressing the unmet medical need of patients suffering from a disease where organ transplantation could be a potentially lifesaving treatment.”

Leaps by Bayer, a unit of Bayer is investing into solutions to some of today’s biggest challenges in health and agriculture. Previous Leaps investments into potentially breakthrough technologies include Casebia Therapeutics (Cure genetic diseases), BlueRock Therapeutics (Regenerate lost tissue function), Joyn Bio (Reduce environmental impact of farming) as well as Khloris, Century Therapeutics and Pyxis Oncology (Prevent and cure cancer).

Latest News

EY Crosses Milestone to Help Clients Deploy SAP on Microsoft Azure with Strategy and Solution Initiatives

Originally posted on EY.com EY framework addresses customers’ enterprise technology and strategy for long-term value from transformation EY digital delivery platform offers up to 70% savings in migration More large enterprises seek to accelerate innovation and increase agility across their business by migrating their mission-critical SAP-based processes to the cloud….

Novartis @ J.P Morgan 2020

Originally published on novartis.com. From January 13th to 16th 2020, Novartis is attending the J.P Morgan Healthcare Conference in San Francisco. This conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment…

Raj Seshadri Named President, Data & Services for Mastercard

Kevin Stanton appointed chief transformation officer Originally published on newsroom.mastercard.com. Mastercard today announced the appointment of Raj Seshadri as president for the company’s data and services organization, reporting directly to Ajay Banga, president and chief executive officer. She succeeds Kevin Stanton, who has taken on a new role as chief…

Marci Ryvicker To Join Comcast Corporation As Senior Vice President, Investor Relations

Originally posted on Comcast.com  Comcast Corporation announced today that Marci Ryvicker will join the company as Senior Vice President, Investor Relations, in mid-January. She will report to Mike Cavanagh, Chief Financial Officer of Comcast Corporation.  “Marci has tremendous expertise in the media, technology, cable, and broadcast industries, and is one…